Serina Therapeutics, Inc. financial data

Symbol
SER on NYSE
Location
601 Genome Way, Suite 2001, Huntsville, AL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 181 % +144%
Debt-to-equity 500 %
Return On Equity -1.4K % -4431%
Return On Assets -214 % -176%
Operating Margin -20.1K % -5548%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.7M shares +19.9%
Common Stock, Shares, Outstanding 10.5M shares +18.6%
Entity Public Float 38.4M USD +105%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 10.3M shares +16.8%
Weighted Average Number of Shares Outstanding, Diluted 10.3M shares -3.83%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 116K USD -96.3%
Cost of Revenue 40K USD +208%
Research and Development Expense 12.1M USD +101%
General and Administrative Expense 11.4M USD +35.4%
Operating Income (Loss) -23.4M USD -108%
Nonoperating Income (Expense) 4.73M USD +22.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -18.6M USD -153%
Earnings Per Share, Basic 1 USD/shares -381%
Earnings Per Share, Diluted 1 USD/shares -446%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.62M USD +171%
Accounts Receivable, after Allowance for Credit Loss, Current 65K USD +983%
Other Assets, Current 170K USD +18.9%
Assets, Current 11.5M USD +112%
Property, Plant and Equipment, Net 580K USD +11.8%
Operating Lease, Right-of-Use Asset 312K USD -38.7%
Intangible Assets, Net (Excluding Goodwill) 509K USD -20.5%
Assets 12.4M USD +67%
Accounts Payable, Current 2.73M USD
Accrued Liabilities, Current 1.14M USD -1.29%
Liabilities, Current 8.79M USD -35%
Operating Lease, Liability, Noncurrent 148K USD -52.6%
Liabilities 10.8M USD -49.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4K USD
Retained Earnings (Accumulated Deficit) -60.2M USD -44.7%
Stockholders' Equity Attributable to Parent 1.76M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.59M USD
Liabilities and Equity 12.4M USD +67%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.32M USD -174%
Net Cash Provided by (Used in) Financing Activities 4.92M USD +80.2%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 40M shares 0%
Common Stock, Shares, Issued 10.5M shares +18.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 595K USD -47.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD -92.9%
Deferred Tax Assets, Valuation Allowance 35.4M USD +176%
Deferred Tax Assets, Gross 35.7M USD +175%
Operating Lease, Liability 311K USD -38.9%
Depreciation 0 USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.59M USD -425%
Lessee, Operating Lease, Liability, to be Paid 335K USD -40.1%
Property, Plant and Equipment, Gross 1.23M USD +25.5%
Operating Lease, Liability, Current 163K USD -17.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 117K USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 159K USD -26.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 24K USD -52%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10K USD -91.5%
Deferred Tax Assets, Operating Loss Carryforwards 22.5M USD +121%
Preferred Stock, Shares Issued 965K shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 816K USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 10K USD
Operating Lease, Payments 56K USD +1.82%
Additional Paid in Capital 57M USD +105%
Preferred Stock, Shares Outstanding 965K shares
Amortization of Intangible Assets 101K USD -22.9%
Deferred Tax Assets, Net of Valuation Allowance 226K USD +61.4%
Share-based Payment Arrangement, Expense 3.83M USD +138%
Interest Expense 4.91M USD +72.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%